SCHEMBL1250702

SCHEMBL1250702

Oc1ccc(-c2noc(-c3ccc4[nH]nnc4c3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
HSD17B10 Q99714 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
PKM P14618 2/20 0.41
MAPT P10636 2/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MAOB P27338 2/20 0.40
RAB9A P51151 4/20 0.39
NR1H4 Q96RI1 2/20 0.38
S1PR1 P21453 2/20 0.38
PSMD11 O00231 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23523835 0.88 SMN1; SMN2 (0.56) NPC1SMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL1607080 0.83 RAB9A (0.56) NPC1SMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL1423111 0.80 NPC1 (0.60) NPC1SMN1; SMN2HSD17B10KDM4EALDH1A1
SCHEMBL1608471 0.78 PSMD11 (0.54) NPC1SMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL30355526 0.78 SMN1; SMN2 (0.48) NPC1SMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL23523836 0.78 SMN1; SMN2 (0.48) NPC1SMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL1250913 0.77 NPC1 (0.46) NPC1SMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL23524022 0.77 SMN1; SMN2 (0.57) NPC1SMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL30355615 0.77 SMN1; SMN2 (0.57) NPC1SMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL12270961 0.76 NPC1 (0.54) NPC1SMN1; SMN2HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US claimed
EP-2285789-A1 NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES Merck Sharp & Dohme Corp. (US) 2011-02-23 EP claimed
WO-2009146343-A1 NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES MERCK & CO., INC. (US) 2009-12-03 WO claimed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 US disclosed
WO-2009146343-A1 NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES MERCK & CO., INC. (US) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles APP, PSEN1, BACE1 NPC1 129/4885SMN1; SMN2 2239/4885HSD17B10 2679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.